Rheumatology Advances in Practice最新文献

{"title":"Physical fitness and physical activity in psoriatic arthritis: a systematic review.","authors":"Marlies Kaerts, Thijs W Swinnen, Wim Dankaerts, Kurt de Vlam, Barbara Neerinckx","doi":"10.1093/rap/rkaf066","DOIUrl":"10.1093/rap/rkaf066","url":null,"abstract":"<p><strong>Objectives: </strong>Despite the increased cardiometabolic risk in psoriatic arthritis (PsA) and the known beneficial effects of physical fitness (PF) and physical activity (PA) on cardiometabolic health, evidence of the current status of PF and PA in PsA is still unclear. Therefore, this study aimed to systematically review research on PF and PA in PsA.</p><p><strong>Methods: </strong>A systematic literature search using four databases was performed to include studies examining PF, specifically cardiorespiratory (CRF) and muscular fitness (MF), and PA in patients with PsA (PROSPERO ID 255501). Risk of bias (RoB) assessment was conducted. Due to the diversity of outcomes, a narrative synthesis was used.</p><p><strong>Results: </strong>Eighteen papers reporting PF and 33 papers examining PA were included. RoB was low in two studies assessing PF and in four PA studies. CRF was evaluated in two studies, indicating CRF levels similar to a sedentary general population. Handgrip strength (HGS) was reduced in PsA compared with healthy controls, but results concerning additional MF parameters were inconclusive. Three studies measured PA objectively and eight studies used a validated PA questionnaire, suggesting a decreased PA level in PsA. A negative impact of low PA and CRF levels on disease onset was observed. In contrast, a potential negative effect of biomechanical loading on disease parameters (disease onset, disease activity, structural joint and enthesial damage) was suggested.</p><p><strong>Conclusion: </strong>Current literature suggests a reduced PA level and decreased HGS, but is inconclusive regarding additional MF outcomes. Data on CRF are limited in PsA. Further robust methodological longitudinal and interventional research is needed to examine the relation between PF and PA on PsA disease parameters and cardiometabolic risk.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 3","pages":"rkaf066"},"PeriodicalIF":2.1,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early, integrated systemic sclerosis palliative care for patients and their caregivers: description of a new model of care.","authors":"Julie McDonald, Carolyn Wicks, Laura Ross","doi":"10.1093/rap/rkaf052","DOIUrl":"10.1093/rap/rkaf052","url":null,"abstract":"<p><strong>Objectives: </strong>SSc is a complex, multiorgan disease, associated with the early onset of significant symptoms, impaired quality-of-life and increased mortality due to cardiopulmonary disease. While palliative care could potentially impact the quality of life of patients and caregivers, there is currently no evidence that examines the role or efficacy of palliative care in SSc. This study describes the model of care provided in a clinic of early, integrated palliative care for patients with advanced SSc and their caregivers at a tertiary hospital.</p><p><strong>Methods: </strong>A prospective audit of the palliative care clinic's model of care was conducted during its first 12 months. Descriptive data quantified which aspects of care the patients and caregivers engaged with.</p><p><strong>Results: </strong>Between 01/07/2023 and 01/07/2024, 24 patients received 52 clinic reviews. Disease-directed management was changed for 50% of patients. Pharmacological management was prescribed for 88%. Psychological assessment and support was provided for 96% of patients and caregivers, while social support assessment was conducted for 100%. The majority of patients (88%) accepted serious illness discussion, while 58% engaged in a prognostic discussion. Advance care planning discussions were common (83%), while 42% of patients completed an advance care directive and 46% completed a medical power of attorney. Informal multidisciplinary team discussion occurred for 83% of patients.</p><p><strong>Conclusion: </strong>This clinic provided disease-orientated, multidisciplinary care alongside symptom management, psychosocial support and serious illness communication. The high uptake of key tasks signals a previously unmet palliative care need and suggests this model of care may be acceptable to patients and caregivers.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 2","pages":"rkaf052"},"PeriodicalIF":2.1,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hot, swollen or stiff joints in children and young people: British Society for Rheumatology guideline scope.","authors":"Lisa Bray, Alice Leahy, Alexander Aarvold, Hana Bailey, Jason Barling, Richard Beesley, Christine Chew, Coziana Ciurtin, Ellie Elliott, Kirsten Healy, Katie Hughes, Polly Livermore, Clare Matthews, Joanne May, Alasdair Munro, Lucy Paterson-Brown, Stéphane Paulus, Olivia Playfair, Amanda Rhodes, Binita Shah, Marcus Sim, Katy Walker, Eloise Whitaker, James Galloway","doi":"10.1093/rap/rkaf047","DOIUrl":"10.1093/rap/rkaf047","url":null,"abstract":"<p><p>The objective of this guideline is to provide up-to-date, evidence-based recommendations for the management of children and young people (CYP) who present with one or more hot, swollen or stiff joints. It will incorporate assessment, diagnosis, monitoring, non-pharmacological and initial pharmacological management preceding definitive diagnosis. This is the first British Society for Rheumatology guideline for hot, swollen or stiff joints in CYP <18 years of age and will complement the hot, swollen joint guideline created for adults ≥18 years of age. The guideline will be developed using the methods and rigorous processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.4.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 2","pages":"rkaf047"},"PeriodicalIF":2.1,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor-induced inflammatory arthritis with severe joint destruction requiring knee arthroplasty.","authors":"Hirokazu Taguchi, Yoshitaka Ueda, Yuichi Nagase, Naoto Yokogawa","doi":"10.1093/rap/rkaf067","DOIUrl":"10.1093/rap/rkaf067","url":null,"abstract":"","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 3","pages":"rkaf067"},"PeriodicalIF":2.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C1q monogenic lupus: a case series and review.","authors":"Israrul Haque, Kaustav Mitra, Geetabali Sircar, Parasar Ghosh, Sumantro Mondol, Subhankar Haldar, DipendraNath Ghosh, Rashmi Roongta","doi":"10.1093/rap/rkaf064","DOIUrl":"10.1093/rap/rkaf064","url":null,"abstract":"<p><strong>Objectives: </strong>Monogenic systemic lupus erythematosus (SLE) is caused by a single gene mutation. C1q deficiency is a rare but well-documented form of monogenic SLE, characterized by unique clinical and laboratory indicators that guide diagnosis and treatment. We aimed to describe four cases of C1q monogenic lupus.</p><p><strong>Methods: </strong>This retrospective, single-centre observational study reviews the clinical and serological profiles and outcomes of four cases of C1q Monogenic Lupus diagnosed at our centre. The study was approved by the Institutional Ethics Committee at the Institute of Postgraduate Medical Education and Research (IPGMER), Kolkata-700020 (Memo No. IPGME&R/IEC/2025/0020).</p><p><strong>Results: </strong>We describe four cases of C1Q monogenic lupus identified by whole exome sequencing. All patients exhibited mucocutaneous involvement, discoid lupus erythematosus, inflammatory polyarthritis, normal serum complements C3 and C4, coarse-speckled Antinuclear antibody positivity and antibodies to ribonucleoprotein. Unique features identified include brain parenchymal calcification in one case, chronic subdural haemorrhage in two cases, infection complicated by macrophage activation syndrome in two cases and myositis in one case. Patients were treated with conventional immunosuppressive therapy (glucocorticoids, mycophenolate, cyclophosphamide) and Fresh Frozen Plasma. Our findings were compared with existing literature on C1q deficiency, noting frequent presentations with mucocutaneous and musculoskeletal manifestations, normal C3 and C4 levels and absence of anti-dsDNA antibodies.</p><p><strong>Conclusion: </strong>C1Q Monogenic SLE should be suspected in juvenile SLE patients presenting at under 10 years, with a family history of consanguinity, predominant mucocutaneous manifestations, a history of recurrent infection, normal serum complements and absence of C1q staining in direct immunofluorescence of renal biopsy. In our series, autoimmune manifestations responded well to immunosuppressive therapy.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 3","pages":"rkaf064"},"PeriodicalIF":2.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144485761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The risk of interstitial lung disease in psoriatic arthritis versus psoriasis: a retrospective nationwide database analysis (2014-24).","authors":"Andrew Engel, Christopher Xie, Ross Summer, Giorgos Loizidis","doi":"10.1093/rap/rkaf059","DOIUrl":"10.1093/rap/rkaf059","url":null,"abstract":"<p><strong>Objectives: </strong>Psoriasis (PsO) is a systemic autoimmune disease primarily characterized by erythematous plaques on the skin. While extra-dermal manifestations like psoriatic arthritis (PsA) are well recognized, data linking PsO to interstitial lung disease (ILD) remain limited. This study aimed to evaluate whether patients with PsA have a higher risk of developing ILD compared with patients with PsO.</p><p><strong>Methods: </strong>A retrospective analysis of the TriNetX US database (2014-24) was performed. Adult patients with PsO or PsA treated with systemic immunosuppressive medications were included, excluding those with other autoimmune diseases. ILD risk in PsO and PsA cohorts was compared with a reference population without autoimmune disease. Propensity score matching (PSM) adjusted for age, sex, race, BMI, smoking status and medications known to cause ILD was performed. Baseline immunosuppressive therapies were included in the PSM when comparing PsO and PsA. Statistical significance was determined using the χ² test of independence.</p><p><strong>Results: </strong>After PSM, PsA patients (<i>n</i> = 13 168) had a significantly higher ILD risk compared with the general population (<i>n</i> = 13 168) (risk ratio [RR] 1.94; 95% CI 1.29-2.92; <i>P</i> = 0.0011). PsO patients (<i>n</i> = 24 039) showed no significant difference in ILD risk compared with controls (<i>n</i> = 23 786) (RR 0.79; 95% CI 0.57-1.08; <i>P</i> = 0.14). PsA (<i>n</i> = 13 838) exhibited an over 1.5 times increase in ILD risk compared with PsO (<i>n</i> = 13 842) (RR 1.52; 95% CI 1.06-2.20; <i>P</i> = 0.0226).</p><p><strong>Conclusions: </strong>PsA was associated with a significantly higher likelihood of developing ILD compared with PsO without inflammatory arthritis. These findings underscore the importance of respiratory monitoring in PsA and highlight the need for further studies.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 3","pages":"rkaf059"},"PeriodicalIF":2.1,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12161981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline 25-hydroxyvitamin D levels predict the effects of vitamin D supplementation on joint symptoms and cartilage loss in patients with knee osteoarthritis.","authors":"Tian Wang, Shuang Zheng, Xingzhong Jin, Han Cen, Zhaohua Zhu, Weiyu Han, Anita Wluka, Flavia Cicuttini, Peihua Cao, Changhai Ding","doi":"10.1093/rap/rkaf061","DOIUrl":"10.1093/rap/rkaf061","url":null,"abstract":"<p><strong>Objectives: </strong>To examine whether the baseline vitamin D level modifies the effects of vitamin D supplementation on knee symptoms and cartilage loss in patients with symptomatic knee OA.</p><p><strong>Methods: </strong>This was a post hoc analysis for the VIDEO study, which was a large (<i>n</i> = 413), randomized, double-blind, placebo-controlled clinical trial in knee OA patients with 25-hydroxyvitamin D [25(OH)D levels ranging from 12.5 to 60 nmol/l]. Knee pain was assessed using the WOMAC pain scale. MRI scans of the knee were obtained. Cartilage volume, cartilage defects (0-4) and bone marrow lesions were measured or graded. Classification trees were applied to categorize the subgroups.</p><p><strong>Results: </strong>A total of 413 participants (mean age 63.2 years; 50% women) were randomly assigned to vitamin D and placebo groups. A baseline 25(OH)D level of 43 nmol/l was found as the cut-off value. For the total WOMAC score, vitamin D supplementation decreased more than placebo in patients with 25(OH)D levels of 12.5-43 nmol/l (-256.41 <i>vs</i> -72.10, <i>P</i> = 0.0060) over 2 years but not in those with 25(OH)D levels of 43-60 nmol/l. Comparatively, vitamin D supplementation reduced the total cartilage volume loss (-0.21 <i>vs</i> -0.31, <i>P</i> = 0.0415) and total cartilage defects progression (0.26 <i>vs</i> 0.92, <i>P</i> = 0.0029) in patients with 25(OH)D levels of 43-60 nmol/l but not in those with 25(OH)D of 12.5-43 nmol/l.</p><p><strong>Conclusion: </strong>Supplementation of vitamin D in patients with OA who have 25(OH)D levels ≤43 nmol/l could relieve pain and improve physical function, while in OA patients with 25(OH)D levels >43 nmol/l, supplementation may ameliorate cartilage lesions.</p><p><strong>Trial registration: </strong>clinicaltrials.gov, NCT01176344; anzctr.org.au, ACTRN12610000495022.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 3","pages":"rkaf061"},"PeriodicalIF":2.1,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What's new in the assessment of lupus activity?","authors":"Ana Isabel Ramos-Lisbona, Nur Azizah Allameen, David A Isenberg","doi":"10.1093/rap/rkaf062","DOIUrl":"10.1093/rap/rkaf062","url":null,"abstract":"<p><p>Capturing disease activity in SLE remains challenging. The binary nature of global score indices such as the SLEDAI 2000 (SLEDAI-2K) poses limitations, while the complexity of the BILAG-2004 index requires training and more time investment. Recent efforts to improve SLE activity indices include the SLE Disease Activity Score (SLE-DAS) and Easy-BILAG system. This review analyses the main indices used to assess SLE activity, examines their progressive refinements, evaluates their advantages and limitations and aims to identify the optimal index. The SLE-DAS offers greater sensitivity than the SLEDAI-2K and the Easy-BILAG simplifies scoring while maintaining the comprehensiveness of the BILAG-2004. Composite indices like the SLE Responder Index and BILAG-based Composite Lupus Assessment integrate the SLEDAI-2K and BILAG-2004 but are mainly used in clinical trials due to their complexity. This review emphasizes the importance of balancing sensitivity, specificity, simplicity and comprehensiveness in lupus activity measurement. The search for the optimal index remains ongoing.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 3","pages":"rkaf062"},"PeriodicalIF":2.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychosocial burden of axial spondyloarthritis and impact of different disease domains: a systematic literature review.","authors":"Denis Poddubnyy, Uta Kiltz, Abhijeet Danve, Grace Wright, Rebecca Haberman, Ana Biljan, Jerry Clewell, Jamie Urbanik, Heather Jones, Marina Magrey","doi":"10.1093/rap/rkaf063","DOIUrl":"10.1093/rap/rkaf063","url":null,"abstract":"<p><strong>Objective: </strong>To assess the psychosocial impact of axial spondyloarthritis (axSpA).</p><p><strong>Methods: </strong>A literature search was conducted in two stages: stage 1 included all patients with axSpA and stage 2 focused on patients with inadequate response to prior TNF inhibitor treatment. Selection criteria included population (adults with axSpA), outcomes of interest (psychosocial factors potentially impacted by axSpA, e.g. quality of life, mental health and work productivity) and context [disease-related (disease activity, pain) and -unrelated (gender, race, ethnicity, behaviour) factors potentially affecting psychosocial outcomes). Search results were categorized based on the core domains of disease activity, pain, morning stiffness, fatigue, physical function and overall functioning and health in patients with axSpA.</p><p><strong>Results: </strong>A total of 197 articles were included in this review, most of which were observational, with only one randomized controlled trial (RCT). The evidence suggests an association between greater disease burden and poorer psychosocial outcomes as well as a bidirectional relationship between disease components and psychosocial outcomes, both contributing to the overall disease burden. However, while many studies reported on psychosocial outcomes, potential relationships with disease domains or activity were not evaluated. Furthermore, there were inconsistencies across studies in how these outcomes were measured, such as the use of different tools and/or scales.</p><p><strong>Conclusion: </strong>Given the paucity of RCTs examining psychosocial outcomes in axSpA, future research should focus on standardizing assessment of psychosocial impairments experienced by patients and establishing appropriate interventions and management strategies to ensure the holistic treatment of patients with axSpA and to optimize treatment response and outcomes.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 3","pages":"rkaf063"},"PeriodicalIF":2.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Coping with Health Injuries and Problems questionnaire in a longitudinal cohort with recent-onset RA.","authors":"Zafer Akman, Gilles Boire, Nathalie Carrier, Sophie Roux, Ariel Masetto, Artur J de Brum-Fernandes, Patrick Liang, Hugues Allard-Chamard","doi":"10.1093/rap/rkaf057","DOIUrl":"10.1093/rap/rkaf057","url":null,"abstract":"<p><strong>Objective: </strong>To validate the Coping with Health Injuries and Problems (CHIP) questionnaire in a prospective cohort of early RA patients.</p><p><strong>Methods: </strong>Between 2006 and 2022, newly diagnosed RA patients self-administered CHIP at baseline and at follow-up visits. The original CHIP comprises four subscales (Distraction, Palliative, Instrumental, Emotional preoccupation), each containing eight items (scores 8 to 40). At inclusion and again after more than 2 years of follow-up, internal consistency was assessed with Cronbach's alpha, factor structure with exploratory and confirmatory factor analyses (EFA, CFA), and sensitivity to change with mixed linear models with repeated measures.</p><p><strong>Results: </strong>In 381 early RA patients, the means (SD) were 23.75 (6.52) for Distraction, 23.55 (6.11) for Palliative, 31.38 (5.41) for Instrumental and 25.11 (7.89) for Emotional preoccupation, values comparable to the literature only available in back pain patients. In 253 of the 381 patients followed up into established RA, all subscales except Distraction had decreased significantly between inclusion and follow-up. Internal consistency was similar in established and early RA (Cronbach's alphas: 0.77 to 0.89 <i>vs</i> 0.75 to 0.86, respectively). EFA in early and established RA suggested that three items linked to treatment adherence consistently segregated from other Instrumental items as a subscale, although this did not improve internal consistency and CFA significantly.</p><p><strong>Conclusion: </strong>The original CHIP possesses good psychometric properties to describe individual coping styles in both early and established RA. Coping in RA might be better characterized using five rather than four subscales, with the additional subscale addressing treatment adherence.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"9 3","pages":"rkaf057"},"PeriodicalIF":2.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}